Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) has received a consensus rating of “Moderate Buy” from the thirteen brokerages that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, eleven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $58.1111.

Several research firms have issued reports on TERN. Mizuho upped their price objective on shares of Terns Pharmaceuticals from $33.00 to $54.00 and gave the company an “outperform” rating in a research note on Tuesday, December 9th. UBS Group raised Terns Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, December 4th. Citigroup reiterated an “outperform” rating on shares of Terns Pharmaceuticals in a research report on Wednesday, November 26th. Oppenheimer raised their price objective on shares of Terns Pharmaceuticals from $28.00 to $58.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 9th. Finally, Citizens Jmp upped their target price on shares of Terns Pharmaceuticals from $35.00 to $57.00 and gave the company a “market outperform” rating in a report on Thursday, December 11th.

Terns Pharmaceuticals Trading Down 0.6%

Shares of NASDAQ:TERN opened at $39.35 on Thursday. The company has a market capitalization of $4.08 billion, a PE ratio of -38.20 and a beta of -0.28. Terns Pharmaceuticals has a twelve month low of $1.87 and a twelve month high of $48.26. The firm has a 50 day simple moving average of $38.52 and a 200-day simple moving average of $21.95.

Insider Buying and Selling

In other news, CEO Amy L. Burroughs sold 14,583 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $39.19, for a total transaction of $571,507.77. Following the completion of the sale, the chief executive officer owned 288,976 shares in the company, valued at $11,324,969.44. This represents a 4.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Emil Kuriakose sold 1,155 shares of Terns Pharmaceuticals stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $38.57, for a total transaction of $44,548.35. Following the completion of the transaction, the insider owned 50,365 shares in the company, valued at approximately $1,942,578.05. This trade represents a 2.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 155,826 shares of company stock valued at $5,882,597 over the last ninety days. 1.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Terns Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. AlphaQuest LLC boosted its holdings in Terns Pharmaceuticals by 9,088,200.0% during the third quarter. AlphaQuest LLC now owns 90,883 shares of the company’s stock worth $683,000 after buying an additional 90,882 shares in the last quarter. DLD Asset Management LP acquired a new stake in shares of Terns Pharmaceuticals during the 2nd quarter valued at approximately $138,000. Candriam S.C.A. boosted its stake in shares of Terns Pharmaceuticals by 9.9% during the 2nd quarter. Candriam S.C.A. now owns 2,368,235 shares of the company’s stock worth $8,834,000 after acquiring an additional 214,266 shares in the last quarter. Franklin Resources Inc. purchased a new stake in shares of Terns Pharmaceuticals during the 2nd quarter worth approximately $4,765,000. Finally, JPMorgan Chase & Co. grew its holdings in shares of Terns Pharmaceuticals by 90.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 682,708 shares of the company’s stock worth $5,127,000 after acquiring an additional 324,502 shares during the period. Hedge funds and other institutional investors own 98.26% of the company’s stock.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.